Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Transactions
Holdings
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other


Tags
Quarterly results
Appointed director
CC transcript

Xencor Inc (XNCR) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/03/2023 8-K Quarterly results
Docs: "Xencor Reports Second Quarter 2023 Financial Results"
05/08/2023 8-K Quarterly results
Docs: "Xencor Reports First Quarter 2023 Financial Results"
02/23/2023 8-K Quarterly results
Docs: "Xencor Reports Fourth Quarter and Full Year 2022 Financial Results"
11/07/2022 8-K Investor presentation, Quarterly results
Docs: "-- XmAb564, engineered IL-2 cytokine, is well-tolerated and generates a durable, dose-dependent and selective expansion of Tregs in single-dose, healthy volunteer study --"
08/03/2022 8-K Quarterly results
Docs: "-- Management to Host Conference Call at 4:30 p.m. ET Today --"
05/05/2022 8-K Quarterly results
02/23/2022 8-K Quarterly results
Docs: "-- Management to Host Conference Call at 4:30 p.m. ET Today --"
11/08/2021 8-K Quarterly results
Docs: "-- Management to Host Conference Call at 4:30 p.m. ET Today --"
08/04/2021 8-K Quarterly results
Docs: "-- Management to Host Conference Call at 4:30 p.m. ET Today --"
05/05/2021 8-K Quarterly results
02/23/2021 8-K Quarterly results
11/05/2020 8-K Quarterly results
Docs: "-- Management to Host Conference Call at 4:30 p.m. EST Today --"
08/04/2020 8-K Quarterly results
05/07/2020 8-K Quarterly results
Docs: "Xencor Reports First Quarter 2020 Financial Results"
02/24/2020 8-K Quarterly results
11/05/2019 8-K Quarterly results
Docs: "Xencor Reports Third Quarter 2019 Financial Results"
08/06/2019 8-K Quarterly results
05/09/2019 8-K Quarterly results
Docs: "Xencor Reports First Quarter 2019 Financial Results"
02/25/2019 8-K Quarterly results
11/05/2018 8-K Quarterly results
Docs: "Xencor Reports Third Quarter 2018 Financial Results - Initial Data from Phase 1 Dose-Escalation Study of XmAb®14045 in Acute Myeloid Leukemia to Be Presented at 2018 ASH Annual Meeting - - Plan to Initiate Phase 3 Study of XmAb®5871 in IgG4-Related Disease by Early 2019 - Expect to Initiate Phase 1studies for Bispecific Tumor Microenvironment Activators XmAb®23104 and XmAb®22841 in 1H 2019 - - Management to Host Conference Call at 4:30 pm ET today -"
08/06/2018 8-K Quarterly results
Docs: "Xencor Reports Second Quarter 2018 Financial Results"
05/07/2018 8-K Quarterly results
Docs: "Xencor Reports First Quarter 2018 Financial Results"
02/27/2018 8-K Quarterly results
Docs: "Xencor Reports Fourth Quarter and Full Year 2017 Financial Results"
11/07/2017 8-K Quarterly results
Docs: "Xencor Reports Third Quarter 2017 Financial Results and Provides Clinical Pipeline Update"
08/07/2017 8-K Quarterly results
05/09/2017 8-K Form 8-K - Current report
02/28/2017 8-K Form 8-K - Current report
11/02/2016 8-K Quarterly results
Docs: "Xencor Reports Third Quarter 2016 Financial Results MONROVIA, Calif., — November 2, 2016 — Xencor, Inc. , a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today reported financial results for the third quarter ended September 30, 2016 and provided a review of pipeline and corporate highlights. “During the third quarter, we initiated clinical trials across our internal pipeline of XmAb programs, including Phase 1studies of subcutaneously administered XmAb®5871 and XmAb®7195, and a first-in-human Phase 1study of our lead immuno-oncology bispecific antibody candidate, XmAb®14045,” said Bassil Dahiyat, Ph.D., president and chief executive officer of Xencor. “With these miles..."
08/02/2016 8-K Form 8-K - Current report
05/02/2016 8-K Quarterly results
Docs: "Xencor Reports First Quarter 2016 Financial Results Monrovia, CA — May 2, 2016 — Xencor, Inc. , a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today reported financial results for the first quarter ended March 31, 2016 and provided a review of pipeline and corporate highlights. “During the quarter we initiated Phase 2 trials with XmAb®5871 in both IgG4-Related Disease and systemic lupus erythematosus , two diseases with high unmet need and a strong rationale for B-cell inhibition,” said Bassil Dahiyat, Ph.D., President and Chief Executive Officer of Xencor. “We also continued to advance our broad pipeline of wholly-owned and partnered programs. We remain on track to re..."
03/07/2016 8-K Form 8-K - Current report
11/03/2015 8-K Quarterly results
Docs: "Xencor Reports Third Quarter 2015 Financial Results and Pipeline Update"
08/10/2015 8-K Quarterly results, Conference call transcript
Docs: "Xencor Reports Second Quarter 2015 Financial and Operating Results MONROVIA, Calif. — August 4, 2015 — Xencor, Inc. , a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today reported financial results for the second quarter ended June 30, 2015 and provided a review of its business highlights. “Currently eight XmAb® antibody candidates are in clinical testing, six with partners and two internal. The accelerating momentum of this pipeline of antibodies is a direct result of the breadth of immune biology that our proprietary XmAb platform addresses. We recently unveiled updates on our development plans for our internally-led programs XmAb®5871 in the rare autoimmune disorde...",
"Q2 2015 Xencor, Inc. Earnings Conference Call Transcript"
05/04/2015 8-K Quarterly results
Docs: "Xencor Reports First Quarter 2015 Financial and Operating Results Monrovia, Calif. — May 4, 2015 — Xencor Inc. , a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today reported financial results for the first quarter ended March 31, 2015 and provided a review of business highlights. “Following our equity offering in February, which raised net proceeds of approximately $115 million, we are in a strong financial position to advance our lead pipeline programs and maximize the potential of our XmAb technology,” said Bassil Dahiyat, Ph.D., president and chief executive officer of Xencor. “We started 2015 with two important data readouts which included top-line interim data f..."
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy